Intervention

BG00002 (natalizumab)

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting0

Common conditions4

Lead sponsors shown1

Clinical trials

4 shown

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple SclerosisNCT01058005 · 2010-03-01

A Prospective, Open-label, Non-randomized, Clinical Trial to Determine if Natalizumab (Tysabri®) Improves Ambulatory Measures in Relapsing-remitting Multiple Sclerosis (RRMS) PatientsNCT00871780 · 2009-08-01

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple SclerosisNCT00536120 · 2008-01-01

Natalizumab Re-Initiation of DosingNCT00306592 · 2006-03-01

Common conditions

Multiple Sclerosis1 Multiple Sclerosis, Relapsing-Remitting1 Relapsing Remitting Multiple Sclerosis1 Relapsing Remitting Multiple Sclerosis (RRMS)1

Leading sponsors

Trial status mix

COMPLETED3

TERMINATED1

Phase mix

PHASE32

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.